ImmunityBio and Rafa win Israeli approval for ANKTIVA
Israel's Ministry of Health approves ANKTIVA plus BCG for BCG-unresponsive NMIBC with carcinoma in situ after a four-month accelerated review; Rafa becomes exclusive commercial partner.
See the latest news and media coverage for ImmunityBio. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing immunotherapies for cancer and infectious diseases
immunitybio.comLast updated
In short: ImmunityBio reported Q3 product-revenue growth, but a revenue miss and wider loss sent shares lower.
Israel's Ministry of Health approves ANKTIVA plus BCG for BCG-unresponsive NMIBC with carcinoma in situ after a four-month accelerated review; Rafa becomes exclusive commercial partner.
The randomized QUILT-2.005 trial of 370 BCG-naïve patients showed statistically significant efficacy improvement over BCG alone, with safety consistent with BCG; an sBLA is planned by year-end 2026.
ANKTIVA plus BCG showed 84% cystectomy avoidance at three years. Complete responses lasted beyond 53 months with a favorable safety profile.
The indication now covers BCG-unresponsive non-muscle-invasive bladder cancer with papillary-only tumors, significantly increasing the addressable patient population.
PepGen's PGN-EDODM1 shows positive Phase 2 signals in DM1; Ionis drops 21% on weak Tryngolza launch; ImmunityBio misses Q3 revenue; PsiThera raises $25M.
ImmunityBio stock falls as Q3 revenue misses estimates, despite positive ANKTIVA bladder cancer...
ImmunityBio Inc (NASDAQ:IBRX) shares fell 19% to US$6.97 after the biotechnology company reported a third-quarter revenue shortfall and a sharply wider net loss. The US...
Q3 2026 net product revenue of $48.7 million, up 53% year-over-year, driven by continued adoption among U.S. urologists and strong market access 2026 year-to-date net...
Track ImmunityBio and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to ImmunityBio and other trending companies.